Abstract
With the recent emergence of multidrug-resistant Candida auris, there is an urgent need for new antifungal compounds with novel pharmacodynamic and pharmacokinetic properties that can treat systemic fungal infections caused by this emerging yeast. Historically, testing the efficacy of treatment for disseminated candidiasis was accomplished using a diverse array of in vivo animal models, including mice which offer an advantage both in their similarities to humans and their lower cost of maintenance. However, in order to create effective in vivo models for testing new antifungal compounds designed to treat systemic infections, it is important that these models also mimic several of the relevant predisposing conditions that can lead to disseminated candidiasis. Here, we describe an immunocompromised mouse model of hematogenously disseminated C. auris infection, which may have utility to test the efficacy of candidate antifungal compounds.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Lockhart SR et al (2017) Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 64(2):134–140. https://doi.org/10.1093/cid/ciw691
Piedrahita CT, Cadnum JL, Jencson AL, Shaikh AA, Ghannoum MA, Donskey CJ (2017) Environmental surfaces in healthcare facilities are a potential source for transmission of Candida auris and other Candida species. Infect Control Hosp Epidemiol 38(9):1107–1109. https://doi.org/10.1017/ice.2017.127
Lyman M, Forsberg K, Reuben J et al (2021) Notes from the field: transmission of pan-resistant and echinocandin-resistant Candida auris in health care facilities—Texas and the District of Columbia, January-April 2021. Morb Mortal Wkly Rep 70(29):1022–1023. https://doi.org/10.15585/mmwr.mm7029a2
Horton MV et al (2020) Candida auris forms high-burden biofilms in skin niche conditions and on porcine skin. mSphere 5(1):e00910-19. https://doi.org/10.1128/mSphere.00910-19
Kean R, Brown J, Gulmez D, Ware A, Ramage G (2020) Candida auris: a decade of understanding of an enigmatic pathogenic yeast. J Fungi (Basel) 6(1):30. https://doi.org/10.3390/jof6010030
Keighley C, Garnham K, Harch AJ, Robertson M, Chaw K, Teng JC, Chen SCA (2021) Candida auris: diagnostic challenges and emerging opportunities for the clinical microbiology laboratory. Curr Fungal Infect Rep:1–11. https://doi.org/10.1007/s12281-021-00420-y
Hager CL, Larkin EL, Long LA, Ghannoum MA (2018) Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J Antimicrob Chemother 73(8):2085–2088. https://doi.org/10.1093/jac/dky153
Hager CL, Larkin EL, Long L, Abidi FZ, Shaw KJ, Ghannoum MA (2018) In vitro and in vivo evaluation of the antifungal activity of APX001A/APX001 against Candida auris. Antimicrob Agents Chemother 62(3):e02319-17. https://doi.org/10.1128/AAC.02319-17
Hager CL, Long L, Imamura Y, Ghannoum MA (2019) Experimental animal models of invasive fungal infections. In: Ghannoum MA, Perfect JR (eds) Antifungal therapy, 2nd edn. CRC Press, Boca Raton
Xin H, Mohiuddin F, Tran J, Adams A, Eberle K (2019) Experimental mouse models of disseminated Candida auris infection. mSphere 4(5):e00339-19. https://doi.org/10.1128/mSphere.00339-19
Szabo EK, MacCallum DM (2011) The contribution of mouse models to our understanding of systemic candidiasis. FEMS Microbiol Lett 320(1):1–8. https://doi.org/10.1111/j.1574-6968.2011.02262.x
Wang X et al (2018) The first isolate of Candida auris in China: clinical and biological aspects. Emerg Microbes Infect 7(1):93. https://doi.org/10.1038/s41426-018-0095-0
Herrada J, Gamal A, Long L, Sanchez SP, McCormick TS, Ghannoum MA (2021) In vitro and in vivo antifungal activity of AmBisome compared to conventional amphotericin B and fluconazole against Candida auris. Antimicrob Agents Chemother 65(6):e00306-21. https://doi.org/10.1128/AAC.00306-21
Torres SR, Pichowicz A, Torres-Velez F, Song R, Singh N, Lasek-Nesselquist E, De Jesus M (2020) Impact of Candida auris infection in a neutropenic murine model. Antimicrob Agents Chemother 64(3):e01625-19. https://doi.org/10.1128/AAC.01625-19. PMID: 31818824; PMCID: PMC7038241
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Herrada, J., Roberts, K., Gamal, A., Long, L., Ghannoum, M.A. (2022). An Immunocompromised Mouse Model of Candida auris Systemic Infection. In: Lorenz, A. (eds) Candida auris. Methods in Molecular Biology, vol 2517. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2417-3_25
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2417-3_25
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2416-6
Online ISBN: 978-1-0716-2417-3
eBook Packages: Springer Protocols